Kazia Therapeutics Limited's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kazia Therapeutics Limited's ROA in the fourth quarter of 2025?
Kazia Therapeutics Limited recorded a cumulative net loss of $-21 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -400.47%.

However, within the Healthcare sector 942 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4771.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Jun 30 2024) IV. Quarter
Y / Y Total Assets Change	-57.95 %	-72.36 %	-78.26 %	-71.92 %	12.84 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-21	-27	-27	-27	-27
Return On Assets (TTM)	-400.47 %	-368.98 %	-271.46 %	-191.55 %	-149.92 %
KZIA's Total Ranking	# 4771	#	# 5317	#	# 4748
Total Assets (TTM) in million	6	4	5	6	14
Seq. Total Assets Change	52.14 %	-12.86 %	-24.57 %	-57.95 %	0 %
Seq. Net Income Change	-	-	-	-	-

KZIA's 5 Years Annual ROA >> Back to KZIA Management Effectiveness >> Compare KZIA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 453
Sector	# 943
Overall	# 4699

Return On Assets Statistics
High	Average	Low
-19.34 %	-104.89 %	-341.56 %
(Jun 30 2021)		(Jun 30 2025)

Financial Statements
Kazia Therapeutics Limited's Assets	$ 6 million	KZIA's Balance sheet
Kazia Therapeutics Limited's Income	$ -21 million	Quarterly KZIA's Income Statement
KZIA's Income by Division		See KZIA's Income by Division

Annual Return On Assets	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022	(Jun 30 2021) FY 2021
Y / Y Total Assets Change	-71.92 %	-23.14 %	-19.66 %	-19.72 %	78.08 %
Total Assets in million	6	22	28	35	44
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-21	-27	-20	-25	-8
Annual Return On Assets	-341.56 %	-124.06 %	-72.87 %	-70.51 %	-19.34 %

KZIA's 5 Years Annual ROA >> Back to KZIA Management Effectiveness >> Compare KZIA ROA to its Competitors

More Return On Assets Ratios
KZIA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KZIA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KZIA's Competitors
Subscribers only: Roa for Kazia Therapeutics Limited's Suppliers
Subscribers only: Return On Assets for KZIA's Customers

You may also want to know
KZIA's Roi	KZIA's Inventory Turnover Ratio	KZIA's Growth Rates	KZIA's Dividend Comparisons
	KZIA's Profitability Ratios	KZIA's Asset Turnover Ratio	KZIA's Dividend Growth
KZIA's Roe	KZIA's Valuation Ratios	KZIA's Financial Strength Ratios	KZIA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.